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A Ab bs st tr ra ac ct t
Men who carry mutations in BRCA1 or BRCA2 are at increased risk for prostate cancer. However the efficacy of
prostate screening in this setting is uncertain and limited data exists on the uptake of prostate screening by mutation
carriers. This study prospectively evaluated uptake of prostate cancer screening in a multi-institutional cohort of
mutation carriers. Subjects were unaffected male BRCA1 and BRCA2 mutation carriers, aged 40-69 years, enrolled
in the Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab) and who had
completed a mailed, self-report follow-up questionnaire 3 yearly after study entry. Of the 75 male carriers in
this study, only 26 (35%) had elected to receive their mutation result. Overall, 51 (68%) did not recall having
received a recommendation to have prostate screening because of their family history, but 41 (55%) had undergone
a prostate specific antigen (PSA) test and 32 (43%) a digital rectal examination (DRE) in the previous 3 years.
Those who were aware of their mutation result were more likely to have received a recommendation for prostate
screening (43 vs. 6%, p=0.0001), and to have had a PSA test (77 vs. 43%, p=0.005) and a DRE (69 vs. 29%,
p=0.001) in the previous 3 years. The majority of unaffected males enrolled in kConFab with a BRCA1/2
mutation have not sought out their mutation result. However, of those aware of their positive mutation status,
most have undergone at least one round of prostate screening in the previous 3 years.
The authors of the recent short report summarising
the 2006 AIDIT and IMPACT conference are to be
congratulated on their planned study, which should
provide useful information to guide screening
recommendations for male BRCA1 and  BRCA2
mutation carriers [1]. While knowing about the current
screening behaviours of male BRCA1 and BRCA2
carriers could assist the investigators in maximising
recruitment and adherence to the study, relevant
published data are limited [2].
We recently analysed prospective data on the
uptake of prostate cancer screening in male BRCA1
and BRCA2 mutation carriers, aged 40 to 69 years (the
age for eligibility for the IMPACT study), with no
personal history of cancer, enrolled in the Kathleen
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Breast Cancer (kConFab) Follow-Up Study [3].
kConFab is a cohort of over 1110 families with strong
histories of breast and/or ovarian cancer [4, 5]. Every
three years after enrolment, the Follow-Up Study
collects updated information on cancer events,
screening behaviour, epidemiological and lifestyle risk
factors and preventive strategies from these individuals
using self-report questionnaires [3]. The kConFab
Follow-Up study has ethics approval at all sites from
which participants are recruited.
Since 2001 we have mailed follow-up questionnaires
to 123 male BRCA1 and BRCA2 mutation carriers with
no personal history of cancer, aged 40 to 69 years.
Overall 82 (67%) responded. Of these, seven were
excluded from the current analysis (two had cancer
diagnosed and five had benign prostatic hypertrophy
during the follow-up period). Only 26 of the remaining
75 men (35%) had elected to receive their (positive)
mutation test result after being informed that a genetic
test result was available. The mean follow-up period for
the entire group was 4.2 years and the mean time
between genetic test result disclosure and completion of
the follow-up questionnaire was 2.8 years. The average
age of participants was 53 years, with 32 (43%) under
the age of 50 years.
Overall, a majority of men (68%) did not report
receiving any recommendations regarding prostate
screening guidelines because of their family cancer
history. Those who knew their mutation result were
seven times more likely to report having received
recommendations compared with those who did not
know their mutation status (43 vs. 6%, p=0.0001).
Table 1 shows the reported recommendations received,
with the most common being yearly prostate specific
antigen (PSA) testing and digital rectal examination
(DRE). Table 2 shows the prostate screening actually
undertaken. Overall about half (55%) had had a PSA
test in the previous 3 years, with carriers who knew their
result 80% more likely to have had the test than those
who did not know their genetic test result (77 vs. 43%,
p=0.005). Similarly for digital rectal examination,
overall uptake of the test within the previous 3 years
was 43% and more than twice as likely in men who
knew their result (69 vs. 29%, p=0.001).
In our study, only 35% of men elected to learn their
mutation test results, which is lower than the uptake
rate of about 50% seen for women in the kConFab
Follow-Up Study [6]. The low proportion of men from
BRCA1 and BRCA2 mutation positive families who
chose to learn their mutation status is important. If these
rates apply elsewhere, this could be an impediment to
optimal recruitment to IMPACT. Education of men from
these families about the possible personal health
benefits of genetic testing may improve uptake rates.
There are no Australian population guidelines for
prostate cancer screening in the general population
and current Australian guidelines on management of
familial cancer are silent on the issue of prostate cancer
screening for BRCA1 and BRCA2 mutation carriers [7].
The diversity of recommendations (or not) received by
male mutation carriers in this study is likely a reflection
of the paucity of guidelines. Clearly, more information
is needed on whether prostate screening is effective for
BRCA1 and BRCA2 carriers so that evidence-based
guidelines can be established for the management of
this high risk group. We look forward to the results of
the IMPACT study.
T Ta ab bl le e   2 2. .   Prostate screening undertaken by BRCA1 and BRCA2
mutation carriers
S Sc cr re ee en ni in ng g F Fr re eq qu ue en nc cy y C Ca ar rr ri ie er rs s   a aw wa ar re e    C Ca ar rr ri ie er rs s   u un na aw wa ar re e
o of f   m mu ut ta at ti io on n   r re es su ul lt t o of f   m mu ut ta at ti io on n   r re es su ul lt t
n n= =2 26 6   ( (% %) ) n n= =4 49 9   ( (% %) )
PSA yearly 9 (35) 2 (4)
2 yearly 6 (23) 8 (16)
not regular 5 (19) 11 (23)
not in last  6 (23) 26 (53)
3 years
don’t know 0 2 (4)
DRE yearly 3 (12) 1 (2)
2 yearly 5 (19) 3 (6)
not regular 10 (38) 10 (21)
not in last  8 (31) 34 (69)
3 years
don’t know 0 1 (2)
T Ta ab bl le e   1 1. . Prostate screening recommendations received by BRCA1
and BRCA2 mutation carriers
R Re ec co om mm me en nd de ed d    C Ca ar rr ri ie er rs s   a aw wa ar re e    C Ca ar rr ri ie er rs s   u un na aw wa ar re e   
s sc cr re ee en ni in ng g o of f   m mu ut ta at ti io on n   r re es su ul lt t o of f   m mu ut ta at ti io on n   r re es su ul lt t
n n= =2 26 6   ( (% %) ) n n= =4 49 9   ( (% %) )
PSA and DRE 6 (23) 1 (2)
PSA only 3 (12) 0 (0)
DRE only 2 (8) 2 (4)
No recommendation 12 (46) 39 (80)
Unknown 3 (11) 7 (14)H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(3) 163
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